Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

@article{Roy2013PharmacokineticsOI,
  title={Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.},
  author={Michael J Roy and Keith A Erdman and Anura T Abeyratne and Lisa C Plumb and Kenneth C. Lasseter and Dennis S. Riff and James J. Keirns},
  journal={Clinical pharmacokinetics},
  year={2013},
  volume={52 5},
  pages={385-95}
}
BACKGROUND Conivaptan is a non-peptide dual antagonist of vasopressin V1A and V2 receptors that is approved in the United States as an intravenous formulation for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. The pharmacokinetics of intravenous conivaptan had not been studied in patients with hepatic or renal impairment. OBJECTIVE The objective of this study was to assess the pharmacokinetics and tolerability of intravenous conivaptan in subjects with mild… CONTINUE READING